In clinical applications, it has been found that severe COVID-19 patients presenting with ARDS lead to an increase in pro-inflammatory factors, most notably interleukin 1β (IL-1β), interleukin-6 (IL-6), and TNF (Anka et al., 2021). This evidence concerns the gene IL1B and COVID-19.